Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03918252 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
A Phase 2 study of Mesothelioma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT03918252 is a Phase 2 study of Mesothelioma that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 30 participants, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT03918252, a Phase 2 study of Mesothelioma, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard bi-/tri-modality therapy.
Conditions Studied
Interventions
- DRUG Ipilimumab Injection
- DRUG Nivolumab Injection
Study Locations (3)
Maryland
- Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine - Baltimore
- Johns Hopkins University - Baltimore
Texas
- University of Texas M.D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-10-02 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03918252
The ClinicalTrials.gov registry entry for NCT03918252 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (85% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which Ipilimumab Injection is the first listed.
NCT03918252 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Texas.
Frequently Asked Questions
What is clinical trial NCT03918252 about?
NCT03918252 is a clinical study titled "Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma". The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard bi-/tri-modality therapy.
What is the current status of trial NCT03918252?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2019-10-02. Estimated completion is 2027-06.
What conditions does trial NCT03918252 study?
This clinical trial studies the following conditions: Mesothelioma.
What interventions are being tested in trial NCT03918252?
The interventions under investigation include: Ipilimumab Injection (DRUG), Nivolumab Injection (DRUG).
Who is sponsoring clinical trial NCT03918252?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03918252 being conducted?
This trial has 3 study locations across Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Olaparib in Patients With HRD Malignant Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.